Pharmacological Secondary Prevention of Noncardioembolic Cerebral Infarction/Transitory Ischemic Attack – Presence and Future

Authors: doc. MUDr. Zbyněk Kalita, CSc.
Published in: Cesk Slov Neurol N 2011; 74/107(3): 261-272
Category: Review Article


There is a high risk of ischemic stroke (CVE) recurrence and thus its prevention is important. Prevention is based on a systematic monitoring of primary risk factors and pharmacological prevention with antiplatelet drugs. The single most important risk factor is hypertension; an effective treatment of hypertension significantly reduces the risk of CVE recurrence. The recommended target blood pressure is 130–140/80–85 mmHg. Dyslipidemia and its treatment are also considered as a key measure to reduce the risk of recurrence of ischemic CVE. Diabetes mellitus compensation is an important factor in reducing microvascular and macrovascular complications. Less intensive treatment regimens are being recommended to achieve glycated hemoglobin values between 5.3–6.2%. The antiplatelet agent clopidogrel or a combination of acetylsalicylic acid (ASA) with slow-release dipyridamole are recommended, ASA is an alternative. An intensive development of new molecules, P2Y12 receptor antagonists, continues. These are currently tested in cardiology indications. Recent studies, investigating the effectiveness of new antiplatelet drugs (terutroban, a thrombin receptor antagonist). did not prove higher effectiveness in the secondary prevention of ischemic stroke than ASA.

Key words:
secondary prevention of ischemic stroke – arterial hypertension – hyperlipidemia – hyperglycaemia – antiplatelet drugs – aspirin – dipyridamole – clopidogrel – thrombin receptor antagonist


1. Röther J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P et al. Risk factor profile and management of cerebrovascular patiens in the REACH registry. Cerebrovasc Dis 2008; 25(4): 366–374.

2. Steg GP, Bhatt DL, Wilson PWF, D´Agostino R, Ohman EM, Röther J et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297(11): 1197–1206.

3. Weimar C, Goertler M, Röther J, Ringelstein EB, Darius H, Nabavi DG et al. Systematic risk score evaluation in ischemic stroke patiens (SCALA). J Neurol 2007; 254(11): 1562–1568.

4. Lopez AD, Mathers C, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367(9524): 1747–1757.

5. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J. Heart disease and stroke statistics to 2006 update. A report from American Heart Associa­tion Statistics Committee and Stroke Statistics Subcommitte. Circulation 2006; 113(6): e85–e151.

6. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115(5): e69–e117.

7. Luengo-Fernandez R, Gray AM, Rothwell PM. Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison. Lancet Neurology 2009; 8(3): 235–243.

8. Kalita Z. Léčba hypertenze v sekundární prevenci CMP. In: Kalita Z et al (eds). Akutní cévní mozkové příhody, Praha: Maxdorf 2006: 371–374.

9. Yusuf S, Diener H, Sacco RL, Cotton D, Ounpuu S, Lawton WA et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359(12): 1223–1237.

10. Špinar J, Ondráčková B. Telmisartan v sekundární prevenci. Remedia 2009; 19(2): 122–127.

11. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril or both in patients a high risk for vascular events. N Engl J Med 2008; 358(15): 1547–1559.

12. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11(7): 627–636.

13. Suchopár J, Bultas J. Inhibitory ACE a antagonisté AT1 pro angiotensin II (sartany) využitelné v rámci sekundární prevence kardiovaskulárních příhod, porovnání základních údajů. Remedia 2010; 20(2): 134–139.

14. Widimský J sr. Kombinační léčba hypertenze. Prakt Lék 2007; 87(9): 525–530.

15. Rothwell PM, Howard SC, Dolan E, O´Brien E, Dobson JE, Dahlöf B et al. Effect of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9(5): 469–480.

16. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of hypertension in patiens 80 years of age or older. N Engl J Med 2008; 358(18): 1887–1898.

17. Peters R, Beckett N, Forette F, Tuomilehto J, Clarce R, Ritchie C et al. Incident dementia and blood pressure lowering in the hypertension in very elderly trial cognitive fiction assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 2008; 7(8): 683–689.

18. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25(5): 457–507.

19. Widimský J jr, Cífková R, Špinar J, Filipovský J, Grundmann M, Horký K et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008; 50(1): K5–K22.

20. Cushman WC, Evans GW, Byington RP, Goff DC jr, Grimm RH jr et al, the ACCORD study group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575–1585.

21. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hyperten 2009; 27(11): 2121.

22. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: retrospective meta-analysis of data from 90 056 participants in 14 randomised trial of statin. Lancet 2005; 366(9493): 1267–1278.

23. Kalita Z. Inhibitory HMG-CoA-reduktázy – statiny. In: Kalita Z et al (eds). Akutní cévní mozkové příhody. Praha: Maxdorf 2006: 374–382.

24. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8(5): 453–463.

25. Amarenco P, Benavente O, Goldstein LB, Callahan A, Sillesen H, Hennerici MG et al. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40(4): 1405–1409.

26. Amarenco P, Bogousslavsky J, Callahan A jr, Golstein LB, Hennerici M, Rudolph AE et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355(6): 549–559.

27. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular dinase or other high-risk conditions. Lancet 2004; 363(9411): 757–767.

28. Amarenco P, Bogousslavsky J, Callahan A jr, Goldstein LB, Hennerici M, Rudolph AE et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355(6): 549–559.

29. Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J et al. Atorvastatin reduces the risk of cardiovascular events in patiens with carotid atherosclerosis. Stroke 2008; 39(12): 3297–3302.

30. Afilalo J, Duque G, Steele J, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patiens. J Am Coll Cardiol 2008; 51(1): 37–45.

31. Amarenco P, Glodstein LB, Sillesen H, Benavente O, Zweifler RM, Callahan A jr et al. Coronary heart disease risk in patiens with stroke or transient ischemic attack and no know coronary heart disease. Findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2010; 41(3): 426–430.

32. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB et al. Update the AHA/ASA recommendation for the prevention of stroke in patiens with stroke and transient ischemic attack. Stroke 2008; 39(5): 1647–1652.

33. Amarenco P, Goldstein LB, Messig M, O´Neill BJ, Callahan A jr, Sillesen H et al. Relative and cumulative effects of lipid and blood pressure control in the stroke prevention by aggressive reduction in cholesterol levels trial. Stroke 2009; 40(7): 2486–2492.

34. Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A jr et al. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Redcuction in Cholesterol Levels (SPARCL) trial. Stroke 2009; 40(11): 3526–3531.

35. Ošťádal P. Studie JUPITER. Remedia 2008; 18(6): 438–439.

36. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJP et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195–2207.

37. Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >=5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J 2011; 32(1): 75–83.

38. McArthur K, Lees KR. Advances in stroke. Advances in emerging therapies 2009. Stroke 2010; 41(2): e67–e70.

39. Chatriwalla AK, Nicholls SJ, Nissen SE. The ASTEROIDtrial: coronary plaque regression with high-dose statin therapy. Future Cardiol 2006; 2(6): 651–654.

40. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295(13): 1556–1565.

41. Lardizabal JA, Deedwania PC. Benifits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag 2010; 6: 843–853.

42. Vrablík M. Prevence cévních mozkových příhod hypolipidemickou léčbou. Remedia 2009; 19(2): 144–148.

43. Vaverková H, Soška V, Rosolová H, Češka R, Cifková R, Freiberger T et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti vypracované výborem české společnosti pro aterosklerózu. Čas. Lék. čes. 2007; 146(6): I–XV.

44. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we blind statins monotherapy? Adv Cardiol 2008; 2008, 45: 127–153.

45. Berge KG, Canner PL. Coronary drug project: experience with niacin. Eur J Clin Pharmacol 1991; 40 (Suppl 1): S49–S51.

46. Žák A, Zeman M, Vecka M, Tvrzická E. Kyselina nikotinová: lék neprávem opomíjený. Čas Lék. čes. 2006; 145(11): 825–831.

47. Bláha V. Kombinovaná hypolipidemická léčba u pacientů s vysokým kardiovaskulárním rizikem. Interní Med 2009; 11(1): 7–12.

48. McKenney JM, Jones PH, Bays HE. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus statin alone (the COMPELL study). Atherosclerosis 2007; 192(2): 432–437.

49. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ et al. The ARBITER 6-HALTS Trial (Arterial Biology for Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55(24): 2721–2726.

50. Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009; 5: 901–908.

51. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA et al. Genome-wide association of lipid-lowering response to statins in combined study population. PLoS One 2010; 5(3): e9763.

52. Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr Opin Mol Ther 2008; 10(6): 555–561.

53. Fuentes B, Martinez-Sánchez P, Diéz-Tejedor E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis 2009; 27 (Suppl 1): 126–133.

54. Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovasular patients. Vask Health Risk Manag 2010; 6: 843–53.

55. Brychta T. Kam kráčíte, glitazony? Remedia 2008; 18(4): 287–292.

56. Dormandy JA, Charbonnel B, Eckland D, Erdman E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patiens 2 diabetes in the PROactive Study (PROspective pioglitAzone Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–1289.

57. Koblihová H, Kvapil M. Studie RECORD. Hodnocení vlivu rosiglitazonu na výskyt kardiovaskulárních příhod. Remedia 2009; 19(4): 288–289.

58. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M et al. Rosigitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125–2135.

59. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensit glukose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–1589.

60. Szabó M. Studie ADVANCE – větev intervence hyperglykémie. Remedia 2008; 18(4): 310–312.

61. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT et al. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (Supp12A): 21i–33i.

62. Siegel D, Swislocki AL. The ACCORD Study: The Devil is in the Details. Metab Syndr Relat Disord 2011; 9(2): 81–84.

63. Mitka M. Contradictory findings ignite questions about blood glucuse target in diabetes. JAMA 2008; 299(12): 1413–1415.

64. Fruchart JC, Sacks FM, Herrmans MP. Implication of the ACCORD lipid study: perspective from the residual risk reduction initiative. Curr Med Res Opin 2010; 26(8): 1793–7.

65. Tenenbaum A, Fisman EZ. “If it ain‘ t broke, don‘ t fix it”: a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol 2010; 15: 9–24.

66. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129–139.

67. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545–2559.

68. Ford ES, Bergmann MM, Kröger J, Schienkiewitz A, Weikert C, Boeing H. Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer and Nutrition-Potsdam study. Arch Intern Med 2009; 169(15): 1355–1362.

69. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis 2009; 27(5): 493–501.

70. Kalita Z. Epidemiologie cévních mozkových příhod a dělení. In: Kalita Z et al (eds). Akutní cévní mozkové příhody. Maxdorf 2006: 16–35.

71. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: The A-S-C-O (Phenotypic) classification of stroke. Cerebrovasc Dis 2009; 27(5): 502–508.

72. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Tromb Haemost 2009; 102(2): 248–257.

73. Kalita Z, Keller O, Bar M, Mikulík R, Škoda O, Neumann J. Doporučený postup sekundární prevence recidivy po akutní cévní mozkové příhodě: mozkovém infarktu/tranzitorní ischemické atace a hemoragické cévní mozkové příhodě. Cesk Slov Neurol N 2008; 71/104(3): 372–378.

74. Kalita Z. Acetylsalicylová kyselina a její význam v léčbě a prevenci ischemické cévní mozkové příhody. Cesk Slov Neurol N 2004; 67/100(3): 149–156.

75. Kalita Z. Sekundární medikamentózní prevence. In: Kalita Z et al (eds). Akutní cévní mozkové příhody. Praha: Maxdorf 2006: 337–368.

76. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA. A meta-analysis. Stroke 2008; 39(4): 1358–1363.

77. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367(9558): 1665–1673.

78. Sacco RL, Diener HC, Yusuf S, Cotton DPD, Ounpuu S, Lawton WA et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359(12): 1238–1251.

79. Kalita Z. Clopidogrel v neurologii. Farmakoterapie 2006, 4: 364–368.

80. Rude MK, Chey WD. Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between? Gastroenterology 2009; 137(3): 1168–1171.

81. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Ménevea N et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360(4): 363–375.

82. Shuldiner AR, O´Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB et al. Association of cytochrome P450 2C19 genotype with antiplatelet effect and clinical efficasy of clopidogrel therapy. JAMA 2009; 302(8): 849–857.

83. Mega JL, Close SL, Wiviott SD. Shen L, Hockett RD, Brandt JT et al. Cytochrome P-450 polymorphismus and response to clopidogrel. N Engl J Med 2009; 360(4): 354–362.

84. Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members, Holmes DR jr, Dehmer GJ, Kaul S, Leifer D, O‘Gara PT, Stein CM. ACC/AHA Clopidogrel clinical alert: Approaches to the FDA “boxed warning”. Circulation 2010; 122(5): 537–557.

85. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA,Bates E, Rozenman Y et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 2009; 374(9694): 989–997.

86. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, LeCalvez G et al. Influence of omeprazole on antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51(3): 256–260.

87. Cuisset T, Frero C, Quilici J, Poyet R, Gaborit B, Bali L et al. Comparison of omeprazole and pantoprazole influence on high 150 mg clopidogrele maintance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13): 1149–53.

88. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Romsfeld JS. Risk of adverse outcomes assotiated with concomitant use of clopidogrel and proton pump inhibitors folowing acute coronary syndrome. JAMA 2009; 301(9): 973–44.

89. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function – a flow cytometry study. Eur Heart J 2003; 24(19): 1744–1749.

90. Weinberger J. Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Drug 2005; 65(4): 461–471.

91. Clarke TA, Waskell LS. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31(1): 53–59.

92. Nguyen TA, Diodati JG. Resistance to clopidogrel: a review of evidence. J Am Coll Cardiol 2005; 45(8): 1157–1164.

93. Wiviott SD, Antman EM. Clopidogrel resistence: a new chapter in fast-moving story. Circulation 2004; 109(25): 3064–3067.

94. Shehab N, Sperling LS, Kegler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related averse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med 2010; 170(21): 1926–1933.

95. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367(9526): 1903–1912.

96. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ et al. Pilot study of antiplatelet effect in increased clopidogrel maintance dosing and its relationship to CYP2C19 genotype in patiens with high on-treatment reaktivity. JACC Cardiovasc Interv 2010; 3(10): 1001–1007.

97. Leys D, Balucani C, Cordonnier Ch. Antiplatelet drugs for ischemic stroke prevention. Cerebrovasc Dis 2009; 27 (Suppl 1): 120–125.

98. O’Donnell MJ, Hankey GJ, Eikelboom JW. Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke. A critical review. Stroke 2008; 39(5): 1638–1646.

99. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376(9748): 1233–1243.

100. Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE et al. Evaluation of individual clopidogrel therapy after drug-eluting stent implantation in patiens with high residual platelet reaktivity: design and rationale of the GRAVITAS trial. Am Heart J 2009; 157(5): 814–824.

101. Horowitz JD, Rosenson RS, McMurray JJ, Marx N, Remme WJ. Clinical trials update AHA congress 2010. Cardiovasc Drugs Ther 2011; 25(1): 69–76.

102. Kent DM, Thaler DE. Stroke prevention – insights from incoherence. N Engl J Med 2008; 359(12): 1287–1289.

103. Murdoch D, Plosker GL. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation. Drug 2006; 66(5): 671–692.

104. Alvarez-Sabín J, Penalba A, Quintana M, Krupinski J, Garcia-Bonilla L, Montaner J. Triflusal and aspirin have different effects on inflammatory biomarkers measured in patiens with acute ischemic stroke. Cerebrovasc Dis 2009; 28(4): 371–377.

105. Lee YS, Bae HJ, Lee SH, Rha JH, Lee SJ, Lee JH et al. Cilostazol in acute ischemic stroke treatment (CAIST). Cerebrovasc Dis 2009; 27 (Suppl 6): 81.

106. Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008; 26(1): 63–70.

107. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS et al. Cilostazol prevents the progression of symptomatic intracranial arterial stenosis. The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005; 36(4): 782–786.

108. Matsumoto M. Cilostazol in secondary prevention of stroke: impact of Cilostazol Stroke Prevention Study. Atherosclerosis Suppl 2005; 6(4): 33–40.

109. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K et al. Cilostazol for prevention of secondary stroke (CSPS 2) an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9(10): 959–968.

110. Huang Y, Wu J, Li Y, Xu E, Hong Z, Li Z et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7(6): 494–499.

111. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patiens with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27(9): 1038–1047.

112. Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J. Ticagrelor – a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Med Sci Monit 2009; 15(12): MS24–MS30.

113. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009; 27(4): 259–274.

114. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patiens with acute coronary syndromes. J Am Coll Cardiol 2007; 50(19): 1852–1856.

115. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G et al. Safety, tolerability, and initial efficacy od AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, comprated with clopidogrel, in patiens with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2007; 50(19): 1844–1851.

116. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patiens with acute coronary syndromes. N Engl J Med 2009; 361(11): 1045–1057.

117. Storey RF, Angiolillo DJ, Patil SD, Desai B, Ecob R, Husted S et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet fuction in patiens with acute coronary syndromes. The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56(18): 1456–1462.

118. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei V, Teng R et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation 2010; 121(10): 1188–1199.

119. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005; 31(2): 184–194.

120. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patiens with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371(9621): 1353–1363.

121. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo S, Gottlieb S et al. Prasugrel versus clopidogrel in patiens with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001–2015.

122. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010; 122(4): 394–403.

123. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G et al. Adjusted inderect comprarison meta-analysis of prasugrel versus ticagrelor for parients with acute coronary syndromes. Int J Cardiol. In press 2010.

124. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C et al. Randomized double-blind assessment of the ONSET an OFFSET of antiplatelet effects of ticagrelor versus clopidogrel in patiens with stable coronary artery disease. On ONSET/OFFSET study. Circulation 2009; 120(25): 2577–2585.

125. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009; 7(10): 1195–1201.

126. Norgard NB. Cangrelor: a novel P2Y12 receptor antagonist. Expert Opin Investig Drugs 2009; 18(8): 1219–1230.

127. Šimek S. Studie CHAMPION PLATFORM. Interv Akut Kardiol 2010; 9(3): 158–159.

128. Oestreich JH. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndroma and prevention of secondary thrombotic events. Curr Opin Investig Drugs 2010; 11(3): 340–348.

129. Ueno M, Rao SV, Angiolillo DJ. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol 2010; 6(4): 445–453.

130. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K et al, PERFORM study investigators. The prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with history of ischemic stroke or transient ischemic attack (PERFORM study): baseline characteristics of the population. Cerebrovasc Dis 2009; 27(6): 608–613.

131. Gaussem P, Reny JL, Thalamas C, Chatelain N, Kroumova M, Jude B et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005; 3(7): 1437–1345.

132. Breyer RM, Bagdassarian CK, Myers SA, Beryer MD. Prostanoid receptors: subtypes and signaling. Ann Rev Pharmacol Toxicol 2001; 41: 661–690.

133. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuer TJ, Cohen RA. The tromboxane receptor antagonist S18886 but not aspirin inhibic atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20(7): 1724–1728.

134. Worth NF, Berry CL, Thomas AC, Campbell JH. S 18886, a selective TP receptor antagonist, inhibic development of atherosclerosis in rabbits. Atherosclerosis 2005; 183(1): 65–73.

135. Tolentino AR, Bahou WF. Trombin receptors. In: Michelson AD (ed). Platelets. San Diego: Elsevier Sci 2002: 117–138.

136. Doc ID 3302825. Investigator’s brochure: informatik for the investigational product SCH 530348 bisulfate. Kenilworth (NJ): Schering-Plough Research Institute 2007.

137. Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C et al. A key role of adenosine diphosphate in irreversible platele aggregation induced by the PAR 1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94(12): 4156–4165.

138. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A et al. Safety and tolerability of SCH 530348 in patiens undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373(9667): 919–928.

139. Bauer J. Antikoagulační terapie v prevenci a léčbě ischemických iktů. Cesk Slov Neurol N 2010; 73/106(5): 480–491.

140. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102 (Suppl 10): 1K–34K.

141. Ford ES, Bergmann MM, Kröger J, Schienkiewitz A, Weikert C, Boeing H. Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer and Nutrition-Potsdam Study. Arch Intern Med 2009; 169(15): 1355–1362.

142. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Intervention for enhacing medication adherence. Cochrane Database Syst Rev 2008; 2: CD000011.

143. Rájec J, Kriška M, Bublová A. Hodnotenie compliance u pacientov v rámci aspirínovej prevencie. Klin Farmakol Farm 2008; 22(1): 15–17.

144. Cooper C, Carpenter I, Katona C, Schroll M, Wagner C, Fialova D, Livingston G. The AdHOC study of older adults’ adherence to medicatio countries. Am J Geriatr Psychiatry 2005; 13(12): 1067–1076.

145. Vytřísalová M. Adherence k medikamentózní léč­bě – známá neznámá. Remedia 2009; 19(3): 225–230.

146. Kriška M, Rájec J, Kriška J, Dukát A, Ambrózy E, Gajdošík J. Percepcia rizika pri antiagregačnej preventívnej terapii. Klin Farmakol Farm 2008; 22(1): 11–14.

Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 3

2011 Issue 3

Most read in this issue
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account